PTPA and Alzheimer disease: Previous research shows that, in both sporadic and familial AD patients, there could be observed a decreased level of active β-catenin, inactive PP2A, and hyper active GSK3β (Voronkov et al., 2011; Inestrosa and Varela-Nallar, 2014).